1. Home
  2. CGO vs KRRO Comparison

CGO vs KRRO Comparison

Compare CGO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Calamos Global Total Return Fund

CGO

Calamos Global Total Return Fund

SELL

Current Price

$12.03

Market Cap

126.4M

Sector

Finance

ML Signal

SELL

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

SELL

Current Price

$8.88

Market Cap

142.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CGO
KRRO
Founded
2004
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
126.4M
142.0M
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
CGO
KRRO
Price
$12.03
$8.88
Analyst Decision
Strong Buy
Analyst Count
0
11
Target Price
N/A
★ $20.20
AVG Volume (30 Days)
23.9K
★ 194.3K
Earning Date
01-01-0001
11-11-2026
Dividend Yield
★ 9.25%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$56.67
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 181.46
52 Week Low
$10.71
$5.20
52 Week High
$14.20
$55.89

Technical Indicators

Market Signals
Indicator
CGO
KRRO
Relative Strength Index (RSI) 29.84 35.47
Support Level $11.27 $8.29
Resistance Level $12.11 $9.59
Average True Range (ATR) 0.37 0.66
MACD -0.06 -0.02
Stochastic Oscillator 5.88 27.05

Price Performance

Historical Comparison
CGO
KRRO

About CGO Calamos Global Total Return Fund

Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: